Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of recombinant luteinizing hormone supplementation timing on ART outcomes in POSEIDON group I patients with LH/LHCGR polymorphisms
ChiCTR2200064369Phase 4Not yet recruiting
- Sponsor
- West China Second University Hospital
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of lutropin alfa in infertility (2 arms), sponsored by West China Second University Hospital. Primary endpoint: Number of oocytes retrieved. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
lutropin alfa
03
Conditions
infertility
Beyond the preview
Go deeper on ChiCTR2200064369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064369.